Palmoplantar Keratoderma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major palmoplantar keratoderma markets are expected to exhibit a CAGR of 2.19% during 2024-2034.
The palmoplantar keratoderma market has been comprehensively analyzed in IMARC's new report titled "Palmoplantar Keratoderma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Palmoplantar keratoderma (PPK) is a rare dermatological condition characterized by the thickening of the skin on the palms of the hands and the soles of the feet. This disease falls under the category of hereditary keratinization disorders and can be inherited in an autosomal dominant, autosomal recessive, or X-linked manner. Individuals suffering from the ailment often experience a range of symptoms, including the development of thick, rough, and calloused skin on their palms and soles. This thickening of the skin can lead to discomfort, pain, and reduced dexterity due to the abnormal accumulation of keratin, a protein that provides strength and protection to the skin. In some cases, PPK may also be associated with additional indications, such as blisters, fissures, and redness, further impacting the quality of life. The diagnosis of the disorder involves a clinical examination of the affected areas, taking into consideration the patient's medical history and any family history of similar skin conditions.
The escalating prevalence of genetic mutations affecting proteins responsible for skin cell regulation, particularly those involving keratin, is primarily driving the palmoplantar keratoderma market. In addition to this, the inflating utilization of advanced therapeutic approaches, including topical retinoids, keratolytics, and emollients, aimed at alleviating symptoms and preventing the progression of the disorder, is also creating a positive outlook for the market. Moreover, the widespread adoption of tailored interventions like phototherapy and systemic treatments, as they are effective in managing the condition's severity and improving patients' quality of life, is further bolstering the market growth. Apart from this, the rising usage of minimally invasive procedures, such as laser therapy and microdermabrasion, that target the thickened skin areas by stimulating the production of collagen and promoting skin remodeling is acting as another significant growth-inducing factor. Additionally, the escalating application of physical and occupational therapies, which help in enhancing mobility and minimizing discomfort associated with the disorder, is also augmenting the market growth. Furthermore, the emerging popularity of gene therapy, involving the introduction of functional genetic components to correct or replace malfunctioning genes responsible for PPK, is expected to drive the palmoplantar keratoderma market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the palmoplantar keratoderma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for palmoplantar keratoderma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the palmoplantar keratoderma market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the palmoplantar keratoderma market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the palmoplantar keratoderma market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current palmoplantar keratoderma marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the palmoplantar keratoderma market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the palmoplantar keratoderma market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the palmoplantar keratoderma market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of palmoplantar keratoderma across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of palmoplantar keratoderma by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of palmoplantar keratoderma by gender across the seven major markets?
How many patients are diagnosed (?2018-2034?) with palmoplantar keratoderma across the seven major markets?
What is the size of the palmoplantar keratoderma patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of palmoplantar keratoderma?
What will be the growth rate of patients across the seven major markets?
Palmoplantar Keratoderma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for palmoplantar keratoderma drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the palmoplantar keratoderma market?
What are the key regulatory events related to the palmoplantar keratoderma market?
What is the structure of clinical trial landscape by status related to the palmoplantar keratoderma market?
What is the structure of clinical trial landscape by phase related to the palmoplantar keratoderma market?
What is the structure of clinical trial landscape by route of administration related to the palmoplantar keratoderma market?
The palmoplantar keratoderma market has been comprehensively analyzed in IMARC's new report titled "Palmoplantar Keratoderma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Palmoplantar keratoderma (PPK) is a rare dermatological condition characterized by the thickening of the skin on the palms of the hands and the soles of the feet. This disease falls under the category of hereditary keratinization disorders and can be inherited in an autosomal dominant, autosomal recessive, or X-linked manner. Individuals suffering from the ailment often experience a range of symptoms, including the development of thick, rough, and calloused skin on their palms and soles. This thickening of the skin can lead to discomfort, pain, and reduced dexterity due to the abnormal accumulation of keratin, a protein that provides strength and protection to the skin. In some cases, PPK may also be associated with additional indications, such as blisters, fissures, and redness, further impacting the quality of life. The diagnosis of the disorder involves a clinical examination of the affected areas, taking into consideration the patient's medical history and any family history of similar skin conditions.
The escalating prevalence of genetic mutations affecting proteins responsible for skin cell regulation, particularly those involving keratin, is primarily driving the palmoplantar keratoderma market. In addition to this, the inflating utilization of advanced therapeutic approaches, including topical retinoids, keratolytics, and emollients, aimed at alleviating symptoms and preventing the progression of the disorder, is also creating a positive outlook for the market. Moreover, the widespread adoption of tailored interventions like phototherapy and systemic treatments, as they are effective in managing the condition's severity and improving patients' quality of life, is further bolstering the market growth. Apart from this, the rising usage of minimally invasive procedures, such as laser therapy and microdermabrasion, that target the thickened skin areas by stimulating the production of collagen and promoting skin remodeling is acting as another significant growth-inducing factor. Additionally, the escalating application of physical and occupational therapies, which help in enhancing mobility and minimizing discomfort associated with the disorder, is also augmenting the market growth. Furthermore, the emerging popularity of gene therapy, involving the introduction of functional genetic components to correct or replace malfunctioning genes responsible for PPK, is expected to drive the palmoplantar keratoderma market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the palmoplantar keratoderma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for palmoplantar keratoderma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the palmoplantar keratoderma market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the palmoplantar keratoderma market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the palmoplantar keratoderma market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current palmoplantar keratoderma marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the palmoplantar keratoderma market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the palmoplantar keratoderma market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the palmoplantar keratoderma market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of palmoplantar keratoderma across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of palmoplantar keratoderma by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of palmoplantar keratoderma by gender across the seven major markets?
How many patients are diagnosed (?2018-2034?) with palmoplantar keratoderma across the seven major markets?
What is the size of the palmoplantar keratoderma patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of palmoplantar keratoderma?
What will be the growth rate of patients across the seven major markets?
Palmoplantar Keratoderma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for palmoplantar keratoderma drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the palmoplantar keratoderma market?
What are the key regulatory events related to the palmoplantar keratoderma market?
What is the structure of clinical trial landscape by status related to the palmoplantar keratoderma market?
What is the structure of clinical trial landscape by phase related to the palmoplantar keratoderma market?
What is the structure of clinical trial landscape by route of administration related to the palmoplantar keratoderma market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 PALMOPLANTAR KERATODERMA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 PALMOPLANTAR KERATODERMA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 PALMOPLANTAR KERATODERMA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 PALMOPLANTAR KERATODERMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 PALMOPLANTAR KERATODERMA - UNMET NEEDS
10 PALMOPLANTAR KERATODERMA - KEY ENDPOINTS OF TREATMENT
11 PALMOPLANTAR KERATODERMA - MARKETED PRODUCTS
11.1 List of Palmoplantar Keratoderma Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 PALMOPLANTAR KERATODERMA - PIPELINE DRUGS
12.1 List of Palmoplantar Keratoderma Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. PALMOPLANTAR KERATODERMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. PALMOPLANTAR KERATODERMA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 PALMOPLANTAR KERATODERMA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Palmoplantar Keratoderma - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Palmoplantar Keratoderma - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Palmoplantar Keratoderma - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Palmoplantar Keratoderma - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Palmoplantar Keratoderma - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Palmoplantar Keratoderma - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Palmoplantar Keratoderma - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Palmoplantar Keratoderma - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Palmoplantar Keratoderma - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Palmoplantar Keratoderma - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Palmoplantar Keratoderma - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Palmoplantar Keratoderma - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Palmoplantar Keratoderma - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Palmoplantar Keratoderma - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Palmoplantar Keratoderma - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Palmoplantar Keratoderma - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Palmoplantar Keratoderma - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Palmoplantar Keratoderma - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Palmoplantar Keratoderma - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Palmoplantar Keratoderma - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Palmoplantar Keratoderma - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Palmoplantar Keratoderma - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Palmoplantar Keratoderma - Access and Reimbursement Overview
16 PALMOPLANTAR KERATODERMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 PALMOPLANTAR KERATODERMA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 PALMOPLANTAR KERATODERMA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 PALMOPLANTAR KERATODERMA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 PALMOPLANTAR KERATODERMA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 PALMOPLANTAR KERATODERMA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 PALMOPLANTAR KERATODERMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 PALMOPLANTAR KERATODERMA - UNMET NEEDS
10 PALMOPLANTAR KERATODERMA - KEY ENDPOINTS OF TREATMENT
11 PALMOPLANTAR KERATODERMA - MARKETED PRODUCTS
11.1 List of Palmoplantar Keratoderma Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 PALMOPLANTAR KERATODERMA - PIPELINE DRUGS
12.1 List of Palmoplantar Keratoderma Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. PALMOPLANTAR KERATODERMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. PALMOPLANTAR KERATODERMA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 PALMOPLANTAR KERATODERMA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Palmoplantar Keratoderma - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Palmoplantar Keratoderma - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Palmoplantar Keratoderma - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Palmoplantar Keratoderma - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Palmoplantar Keratoderma - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Palmoplantar Keratoderma - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Palmoplantar Keratoderma - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Palmoplantar Keratoderma - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Palmoplantar Keratoderma - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Palmoplantar Keratoderma - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Palmoplantar Keratoderma - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Palmoplantar Keratoderma - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Palmoplantar Keratoderma - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Palmoplantar Keratoderma - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Palmoplantar Keratoderma - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Palmoplantar Keratoderma - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Palmoplantar Keratoderma - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Palmoplantar Keratoderma - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Palmoplantar Keratoderma - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Palmoplantar Keratoderma - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Palmoplantar Keratoderma - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Palmoplantar Keratoderma - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Palmoplantar Keratoderma - Access and Reimbursement Overview
16 PALMOPLANTAR KERATODERMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 PALMOPLANTAR KERATODERMA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 PALMOPLANTAR KERATODERMA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
